ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy

Zhang, Lu*; Wu, Lingeng; Chen, Qiuying; Zhang, Bin; Liu, Jing; Liu, Shuyi; Mo, Xiaokai; Li, Minmin; Chen, Zhuozhi; Chen, Luyan; You, Jingjing; Jin, Zhe; Chen, Xudong*; Zhou, Zejian*; Zhang, Shuixing*广东省人民医院; 汕头大学; 1
ECLINICALMEDICINE2021-1DOI: 10.1016/j.eclinm.2020.100673
23被引8閱讀
引用收藏
分享

摘要

Background: Hyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy. @@@ Methods: A total of 69 patients treated with anti-PD-1 therapy between March 2017 and January 2020 were included. HPD was determined according to the time to treatment failure, tumour growth rate, and tumour growth rate ratio. Univariate and multivariate analyses were performed to identify clinical variables significantly associated with HPD. A risk model was constructed based on clinical variables with prognostic significance for HPD. @@@ Findings: Overall, 10 (14.49%) had HPD. Haemoglobin level, portal vein tumour thrombus, and Child-Pugh score were significantly associated with HPD. The risk model had an area under the curve of 0.931 (95% confidence interval, 0.844-1.000). Patients with HPD had a significantly shorter overall survival (OS) than that of the patients with non-HPD (p < 0.001). However, there was no significant difference in OS between PD (progressive disease) patients with and without HPD (p = 0.05). @@@ Interpretation: We identified three clinical variables as risk factors for HPD, providing an opportunity to aid the pre-treatment evaluation of the risk of HPD in patients treated with immunotherapy.

學科與關鍵詞

關鍵詞
Hyperprogressive diseaseProgrammed cell death 1Immune checkpoint inhibitorsHepatocellular carcinoma
相關
載入中…

文獻載入失敗,請重試

重試

發表資訊

論文狀態
公開發表
期刊
ECLINICALMEDICINE
發表日期
2021-01
卷期
第 31 卷
頁碼
100673
DOI
10.1016/j.eclinm.2020.100673
成果收錄
SCIE
資助標註
National Natural Science Foundation of China [81571664,81871323, 81801665]; National Natural Science Foundation of Guangdong Province [2018B030311024]; Scientific Research General Project of Guangzhou Science Technology and Innovation Commission [20107010328]; China Postdoctoral Science Foundation [2016M600145]

作者

  • Z

    Zhang, Lu (通訊) (第一作者)

    1

  • W

    Wu, Lingeng

    guangdong prov peoples hosp · shantou univ

查看全部 15 位作者收起作者
  • C

    Chen, Qiuying

    1

  • Z

    Zhang, Bin

    1

  • L

    Liu, Jing

    1

  • L

    Liu, Shuyi

    1

  • M

    Mo, Xiaokai

    1

  • L

    Li, Minmin

    1

  • C

    Chen, Zhuozhi

    1

  • C

    Chen, Luyan

    1

  • Y

    You, Jingjing

    1

  • J

    Jin, Zhe

    1

  • C

    Chen, Xudong (通訊)

    1

  • Z

    Zhou, Zejian (通訊)

    guangdong prov peoples hosp

  • Z

    Zhang, Shuixing (通訊)

    1

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417